<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03441971</url>
  </required_header>
  <id_info>
    <org_study_id>Gore PVC 17-02</org_study_id>
    <nct_id>NCT03441971</nct_id>
  </id_info>
  <brief_title>Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction</brief_title>
  <official_title>Evaluation of the GORE PV1 Device for Replacement of the Pulmonary Valve and Reconstruction of Right Ventricular Outflow Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and performance of the GORE PV1 Device for replacement of&#xD;
      the pulmonary valve and reconstruction of the Right Ventricular Outflow Tract (RVOT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 7, 2018</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Actual">April 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Valve-related mortality and device-related re-intervention</measure>
    <time_frame>6 months</time_frame>
    <description>The composite of valve-related mortality and device-related re-intervention measured at 6 months post-procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI change in right ventricular end diastolic volume index</measure>
    <time_frame>6 months</time_frame>
    <description>Six month change from baseline in right ventricular end diastolic volume index as measured from Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI change in right ventricular end systolic volume index at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Six month change from baseline in right ventricular end systolic volume index as measured from Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI change in left ventricular diastolic volume index at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Six month change from baseline in left ventricular diastolic volume index as measured from Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI change in right ventricular ejection fraction at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Six month change from baseline in right ventricular ejection fraction index as measured from Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echo change in right ventricular diastolic area at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Twelve month change from baseline in right ventricular diastolic area as measured from echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echo change in right ventricular systolic area at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Twelve month change from baseline in right ventricular systolic area as measured from echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echo change in left ventricular end diastolic volume index at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Twelve month change from baseline in left ventricular end diastolic volume index as measured from echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echo change in right ventricular fractional area change at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Twelve month change from baseline in right ventricular fractional area change as measured from echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six month mean pressure gradient &lt;= 40 mmHG</measure>
    <time_frame>6 months</time_frame>
    <description>Number of subjects with mean pressure gradient across conduit (RV to PA) less than or equal to 40 mmHg at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Twelve month mean pressure gradient &lt;= 40 mmHG</measure>
    <time_frame>12 months</time_frame>
    <description>Number of subjects with mean pressure gradient across conduit (RV to PA) less than or equal to 40 mmHg at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six month pulmonary regurgitation &lt; moderate</measure>
    <time_frame>6 months</time_frame>
    <description>Number of subjects with pulmonary regurgitation less than moderate at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Twelve month pulmonary regurgitation &lt; moderate</measure>
    <time_frame>12 months</time_frame>
    <description>Number of subjects with pulmonary regurgitation less than moderate at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device-related re-intervention at 1, 3, 6, 12, 24, 36, 48, and 60 months</measure>
    <time_frame>1, 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Kaplan-Meier estimates of device-related re-intervention summarized at 1, 3, 6, 12 months, and annually through 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at 1, 3, 6, 12, 24, 36, 48, and 60 months</measure>
    <time_frame>1, 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Kaplan-Meier estimates of all-cause mortality summarized at 1, 3, 6, 12 months, and annually through 5 years</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Heart Defects, Congenital</condition>
  <condition>Tetralogy of Fallot</condition>
  <condition>Pulmonary Valve Insufficiency</condition>
  <condition>Pulmonary Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the device on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GORE PV1</intervention_name>
    <description>Implantation of GORE PV1 Device for procedure to replace the pulmonary valve and reconstruct the right ventricular outflow tract (RVOT).</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. A symptomatic or appropriate asymptomatic subject with a native or repaired right&#xD;
             ventricular outflow tract requiring reconstruction with a valved conduit&#xD;
&#xD;
          2. Age â‰¥5 years at the time of informed consent signature.&#xD;
&#xD;
        Note: Additional Inclusion Criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. An artificial valve at another position or will need an artificial valve at another&#xD;
             position (i.e. replacement at the time of index procedure or anticipated within 3&#xD;
             years).&#xD;
&#xD;
          2. Subjects with previously implanted pacemaker (including defibrillators).&#xD;
&#xD;
          3. Major or progressive non-cardiac disease (liver failure, renal failure, cancer) that&#xD;
             has a life expectancy of less than one year.&#xD;
&#xD;
        Note: Additional Exclusion Criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro del Nido, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Tetralogy of Fallot</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Stenosis</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

